Furthermore, downregulation of activating receptors, including NKG2D [as is also seen in IPF (115)], and upregulation of the inhibitory receptor NKG2A, reduce anti-tumor potency (28, 29, 122) (Figure 3). Here, KLRK1 is linked to idiopathic pulmonary fibrosis.